Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.
RMD Open. 2022 Feb;8(1):e002012. doi: 10.1136/rmdopen-2021-002012.
RMD Open. 2022.
PMID: 35121639
Free PMC article.
Clinical Trial.